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            Amendments from Version 1
We have updated our paper in response to the helpful comments 
of the reviewers. The main difference is that we have now tested 
the performance of GAKT 4.0.11.0 and found that it has the same 
problems calling MNVs as the previous version. 
Minor changes include making clear the distinction between 
different solutions to the problem – whether the solutions involved 
changing the variant caller or post-processing of the variant. We 
have also amended the nomenclature used for the simulated 






The rapid progress and reduced cost of Next Generation Sequenc-
ing (NGS) has transformed approaches to genomic research 
and clinical diagnostic testing1. While single-gene tests, for 
instance using Sanger (dideoxy) sequencing, will produce a 
short list of variants which can be manually evaluated, this is not 
feasible for next generation analysis. Sequencing at this scale 
requires highly automated analysis pipelines. High throughput 
sequencing services are dependent on automated tools to annotate 
and classify variants by potential consequence. For this reason, 
it is particularly important that any tools used to call and anno-
tate variants do so accurately without the need for any manual 
assessment to avoid potential misdiagnosis.
Multiple Nucleotide Variants (MNVs)2 present a particular chal-
lenge for automated NGS analysis pipelines. These variants 
consist of multiple Single Nucleotide Variants (SNVs) located 
very close together on the same strand of DNA. The Human 
Genome Variation Society (HGVS) guidelines state that in most 
circumstances, two adjacent substitutions should be classified as a 
single deletion-insertion mutation event, rather than two or more 
separate SNVs3.
MNVs that contain multiple SNVs within the same codon may 
have a significantly different protein consequence than if the 
separate SNVs are annotated independently. For instance, a 
CTG codon (Leu) can be changed to TTG or CTC (two separate 
SNVs) without any protein coding consequence, but when changed 
to TTC (an MNV) the consequence is a missense (see Figure 1). 
Importantly, some MNVs would meet the evidence criteria for 
pathogenicity when called as a single mutational event, but would 
not when each SNV is treated separately4. NGS pipelines that 
annotate these MNVs as two independent SNVs could fail to 
correctly identify a pathogenic variant, potentially negatively 
impacting on clinical care.
Most standard NGS variant calling pipelines, including the 
widely adopted GATK best practices5, do not deal with MNVs 
correctly - calling them as separate SNVs6. Consequently, most 
laboratories using NGS technologies are at risk of miscalling 
these variants. Some NGS variant callers incorporate haplotype 
information to correctly call MNVs7,8. Another approach to cor-
rectly call MNVs is to re-process variant calls, for example using 
the Multi-Nucleotide Variant Annotation Corrector (MAC)9. 
There is also a GATK tool, ReadBackedPhasing10, which 
performs phasing of SNVs based on the overlap between reads 
and uses this information to call variants. However, this tool 
is not part of the current versions of the widely followed GATK 
best practice guidelines.
The scale of the potential problem with MNVs was highlighted 
by the ExAC database. The variants within this data set were 
called using a GATK best practices pipeline which does not rec-
ognise MNVs as single mutation events. Lek et al.6 identified 
an average of 23 MNVs that were incorrectly annotated by the 
Figure 1. Diagram illustrating how Multiple Nucleotide Variants will be misannotated if incorrectly treated as separate variants.
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original analysis within each whole exome in the ExAC data set. 
In total, 778 MNVs where a STOP codon should have been anno-
tated were noted, including multiple examples within known 
dominant disease genes. Crucially, they identified 10 MNVs that 
have previously been reported as pathogenic, but which were 
missed by the original pipeline. The impact of MNVs has also 
been highlighted by the diagnosing developmental disorders 
(DDD) study – Kaplanis et al.11 showed that 2% of de novo vari-
ants appeared as part of MNVs and that these were significantly 
enriched in genes associated with developmental disorders in 
affected children.
HGMDpro is a commercially owned, curated database of 
published putative pathogenic variants associated with human 
genetic disorders widely used by genomic diagnostic and research 
laboratories. There are 628 2bp MNVs, 108 3bp MNVs and 
more than 150 larger MNVs listed within this database. These 
previously reported pathogenic variants are at risk of being inac-
curately called by standard analysis pipelines. These misanno-
tations represent potential misdiagnoses unless this problem is 
fully addressed.
In order to investigate the potential extent of this problem 
for clinical diagnostic services we devised two experiments. 
Firstly, to establish how MNVs are analysed we modified a set 
of NGS data to create simulated MNVs and processed this data 
using both a standard GATK best practices pipeline, and pipelines 
incorporating GATK ReadBackedPhasing10, VarDict7, Platypus12 
or MAC9. Secondly, we re-analysed a cohort of 1447 samples 
previously tested using a targeted panel of genes for diagnosis of 
monogenic diabetes and congenital hyperinsulinism13 to determine 
if any potential diagnoses were missed.
By simulating MNVs in NGS sequencing data and testing for them 
using a typical NGS pipeline employed by an NHS diagnostic 
laboratory, we demonstrate that MNVs are incorrectly annotated 
by standard diagnostic NGS pipelines, potentially generating 
false positive and false negative results and negatively impacting 
on patient care.
Methods
GATK best practices pipeline
The Molecular Genetics Laboratory at the Royal Devon & Exeter 
NHS Foundation Trust routinely uses a targeted NGS testing 
pipeline to interrogate an extended panel of genes associated 
with monogenic diabetes and congenital hyperinsulinism13. This 
uses GATK 3.7.0. The pipeline aligns reads to the hg19/GRCh37 
human reference genome with BWA mem 0.7.1514, applies 
Picard 2.5.0 for duplicates removal15 and GATK IndelRealigner 
for local re-alignment16. GATK haplotypecaller is then used 
to identify variants and these are annotated using Alamut 
batch version 1.5.2 (Interactive Biosoftware, Rouen, France). 
This analysis approach is based on the GATK best practice 
guidelines5. We also tested GATK 4.0.11.0 to see if the problem 
had been corrected in the later version of the software.
Generating simulated MNVs
To determine whether the pipeline correctly annotates MNVs, 
we generated a BAM file containing five simulated MNVs in 
the HNF4A gene. These MNVs are detailed in Table 1. Each 
variant was generated as a homozygous call (GT 1/1 with no 
reads supporting the reference allele). We processed these variants 
with the standard GATK best practices pipeline described above.
This dataset is publicly available at https://github.com/ 
rdemolgen/MNV-test-data to provide a simple method for labo-
ratories to test if their current analysis pipeline will annotate 
MNVs correctly.
Re-processing with alternative tools
To investigate whether using alternative tools results in cor-
rect annotation of MNVs, we re-processed the VCF file of simu-
lated MNVs using GATK 3.6.0 ReadBackedPhasing10 (default 
parameters plus “-maxDistMNP 2 -enableMergeToMNP”) or 
MAC 1.29 then annotated the resulting VCF files using Alamut batch 
version 1.5.2 (Interactive Biosoftware, Rouen, France). We also 
tested re-calling the variants using VarDict 1.47 and Platypus 
0.8.112.
Investigating NGS targeted panel data for MNVs
Using the GATK ReadBackedPhasing tool10, we re-examined a 
set of 1447 samples previously sequenced using a custom panel 
of genes for the diagnosis of monogenic diabetes and congenital 
hyperinsulinism13 to determine if any MNVs with an incorrect 
annotation were present.
Results
Simulated MNVs are miscalled using GATK best practices
All five of the simulated MNVs described above were called 
as two separate SNVs using GATK best practices, and thus 
Table 1. Simulated Multiple Nucleotide Variants within the HNF4A gene. Variants are described 









1 20:43052669_43052671 NM_175914:c.838_840 p.Leu280 CTG TTC
2 20:43053017_43053019 NM_001030004:c.1186_1188 p.*396 TAA TGG
3 20:43056977_43056979 NM_175914:c.1066_1068 p.Ser356 TCC AGC
4 20:43058207_43058209 NM_175914:c.1261_1263 p.Ser421 TCT TGA
5 20:43058219_43058221 NM_175914:c.1273_1275 p.Lys425 AAG AGT
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annotated incorrectly using Alamut batch version 1.5.2 (see 
Table 2). Variant 1 was incorrectly called as two separate syn-
onymous variants (p.Leu280Leu), whereas the correct annota-
tion is an in-frame deletion-insertion that results in the missense 
variant p.Leu280Phe. If used diagnostically this would result in 
a false negative result. Variant 2 alters a stop codon – when the 
MNV is treated correctly this results in a stop loss, however 
when each SNV is called separately the original stop codon is 
maintained presenting the potential for a false negative result. 
Variant 3 should result in annotation of a synonymous variant 
when correctly called, however GATK best practices incorrectly 
recognises this as two separate missense variants (p.Ser356Thr 
and p.Ser356Cys), which could result in a false positive test-
ing result. When treated correctly, variant 4 should create a stop 
codon resulting in a nonsense variant, however it is inaccu-
rately annotated as two variants, a missense (p.Ser421Cys) and 
a synonymous variant (p.Ser421Ser). Variant 5 is called as 
p.Lys425Arg and p.Lys425Asn, whereas it should be called 
as a different missense variant, p.Lys425Ser. This could result 
in either a false positive or a false negative result depending 
on the clinical interpretation of the missense variants.
Simulated MNVs were correctly called using alternative 
software
As described above, when our simulated MNVs are called using 
GATK v3.7.0 best practices they are incorrectly called as two 
separate variants. In contrast when re-analysed using GATK 
ReadBackedPhasing10, MAC9 and Platypus12 the separate SNVs 
are correctly merged into a single MNV in all five cases and the 
MNVs were correctly annotated by Alamut batch 1.5.2 as in-frame 
insertion-deletions. VarDict7 correctly calls four variants but 
fails to call variant 1, which is a CTG to TTC non-consecutive 
change, as a single event. We also tested GATK 4.0.11.0 to 
see if the updated version of the software dealt with MNVs 
differently to older versions but the results were the same.
Variants identified through an NGS diagnostic targeted 
panel are miscalled by GATK best practices
The Molecular Genetics Laboratory at the Royal Devon & 
Exeter NHS Foundation Trust utilises an NGS analysis pipeline 
based on GATK best practices. Having established, using 
simulated data that GATK ReadBackedPhasing10 correctly called 
MNVs, we re-analysed 1447 samples tested on a diagnostic 
panel for monogenic diabetes and congenital hyperinsulinism13 to 
examine if any MNVs had been incorrectly annotated using the 
GATK best practices pipeline.
On four occasions MNVs were found to have been miscalled 
as two separate single base substitution variants (Table 3). In 
three cases the correct annotation for the MNV was a mis-
sense variant; however GATK best practices resulted in two 
different missense variants being called. The fourth MNV 
should also have been called as a missense variant, but was 
























2 TAA TGG p.*396* p.*396* p.*396Trpext*26 False negative 
result
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negative result












INSR GCC TTC p.Ala752Val p.Ala752Ser p.Ala752Phe
EIF2AK3 GAT TCT p.Asp615Ala p.Asp615Tyr p.Asp615Ser
GCK GAG AGG p.Glu421Gly p.Glu421Lys p.Glu421Arg
GCK TAC CAA p.Tyr61* p.Tyr61His p.Tyr61Gln
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all four cases the variants were confirmed by Sanger sequencing 
prior to reporting, manual inspection of this data identified the cor-
rect variant call and thus the correct diagnosis was made. In the 
absence of Sanger sequencing confirmation these incorrect 
annotations have the potential to result in false positive or false 
negative results depending on the clinical interpretation of the 
missense variants.
Discussion
Using simulated MNVs and re-analysing data from a diagnos-
tic NGS targeted gene panel test we have demonstrated that the 
current approach employed by most NGS variant pipelines, 
including GATK best practices, can result in MNVs being mis-
called. There are important implications to this inaccuracy. 
In a diagnostic setting this could result in false positive or nega-
tive test results for patients with potentially serious consequences 
to an individual’s healthcare outcome. The significant number of 
previously published MNVs within known human disease genes 
that are listed within the HGMDPro database provides some 
context to the potential scale of this problem.
The GATK best practice guidelines5 have been widely adopted 
and are employed in the analysis pipelines for the majority of 
diagnostic and research NGS facilities worldwide. Our analy-
sis pipeline, based on GATK best practices, which is currently 
in use at our diagnostic laboratory, failed to correctly call our 
simulated MNVs and four MNVs identified by reanalysis of 
targeted gene panel data.
Our analysis demonstrated that in contrast to GATK best 
practices, alternative tools7,9,12 are available which merge the 
nearby SNVs correctly into a single MNV, which is essential for 
correct annotation of variant consequence. There are two dis-
tinct approaches for correcting the problem, either changing the 
variant caller used to one such as Platypus12 which calls MNVs 
correctly or post-process variant calls with tools such as MAC9 
or ReadBackedPhasing to correct the variant calls. Both solu-
tions present problems integrating into existing pipelines. 
Platypus12 does not produce the same quality metrics mak-
ing it more challenging to integrate into an existing GATK 
based pipeline while ReadBackedPhasing does not maintain 
the quality information from the variant calls, in both cases 
making it difficult to filter variants by quality.  Thus while a 
potential solution for individual laboratories to resolve this 
issue would be the integration of other tools within their NGS 
pipelines that deal with MNVs correctly this will present chal-
lenges integrating them. Additionally, this depends on labora-
tory awareness of this ongoing problem and the potential for 
patient harm that it presents.
In the current versions of the GATK best practices, phas-
ing is performed by GATK HaplotypeCaller, so the 
ReadBackedPhasing software, which previously performed 
this role, is no longer being actively maintained. However, 
while HaplotypeCaller builds haplotypes we have demonstrated 
that it does not correctly utilise the information to call MNVs. 
ReadBackedPhasing calls MNVs but does not provide the quality 
score information for them that is produced for variants by 
HaplotypeCaller, which prevents them from being filtered by 
quality. Thus we suggest that the ideal solution would be for 
the features of software which enable correct calling of MNVs, 
namely the appropriate use of haplotype information, to be 
incorporated into HaplotypeCaller.
Adoption of a solution into the GATK best practices is the opti-
mal solution as it does not require individual laboratories to be 
aware of the problem and adopt bespoke solutions. GATK is 
widely adopted for its ease of use: it provides an integrated suite of 
tools with inputs and outputs in standard formats, it has excellent 
documentation and a large user community solving shared 
problems.
Another important consideration to note is that publicly 
available online variant frequency resources such as gnomAD 
and ExAC are currently based on GATK best practices pipe-
lines. These resources are critical to variant interpretation in rare 
genetic disorders as a key criterion for pathogenicity assigna-
tion is allele frequency4. Currently MNVs are flagged, but still 
represented as multiple separate SNVs within gnomAD and 
ExAC. This means that even where laboratories make changes to 
their local pipeline to correctly call MNVs, their local data for 
these variants will be incompatible with these public resources, 
with allele frequency information being unavailable for those 
MNVs.
In summary, the issue of MNVs being miscalled by the most 
commonly employed NGS analysis pipelines continues to be an 
important issue. Although there are a number of tools available 
that call MNVs correctly, these are not currently being widely 
adopted. Addressing this issue by implementing changes within 
GATK best practices would have the greatest impact on preven-
tion of misdiagnoses resulting from MNV calling inaccuracies and 
also importantly provide compatibility with the online public 
variant frequency databases that are central to current diagnostic 
variant classification.
Key points
• Multi-nucleotide variants (MNVs) are misannotated 
by the most widely used next generation sequencing 
analysis pipelines
• Misannotation of MNVs can result in genetic 
misdiagnosis
• We suggest that individual laboratories should 
consider implementing alternative software to avoid 
misannotation of these variants
• The test data described in this manuscript has been made 
publicly available at https://github.com/rdemolgen/ 
MNV-test-data so that laboratories can verify if their 
analysis pipeline correctly annotates multi-nucleotide 
variants
• We suggest that GATK best practices pipeline should 
implement a solution for MNV misannotation to 
ensure widespread adoption
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als reviewed by the Genetic Data Access Committee.
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